Slingshot members are tracking this event:

Gelesis (PTCHF) Expects Readout of Pivotal Trial GLOW in H1 2017 Evaluating Gelesis100 in Weight Loss in Overweight and Obese Subjects With and Without Type 2 Diabetes

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Management Comment "Gelesis100, our lead product, is a first-in-class therapeutic which is designed to act mechanically in the stomach and small intestine to increase satiety and decrease hunger, resulting in reduced caloric intake and weight loss. Gelesis100 is administered orally as a capsulated device."
Clinical Data Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes
Additional Relevant Details Update on July 12 2017: Gelesis Announces Last Patient Out in the Pivotal Gelesis100 Weight-Loss Study
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 25, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Pivotal Trial, Glow, Gelesis100, Weight Loss, Overweight, Obese Subjects, Type 2 Diabtetes, Prediabetic Patients